Pilot Trial of Biovance Collagen-Based Wound Covering for Diabetic Ulcers

摘要: BACKGROUND: Diabetes mellitus affects more than 194 million people worldwide, resulting in nearly 40,000 limb amputations per year, secondary to infected ulcerations, peripheral neuropathy, and inadequate vascular status. Diabetic foot ulcers have an underlying metabolic etiology that contributes a nonhealing ulcer. Biovance (Celgene Cellular Therapeutics, Morris, New Jersey) is wound covering produced from decellularized, dehydrated human amniotic membrane. The purpose of this study was determine healing rates for partial- full-thickness diabetic treated with Biovance. objective time complete closure safety profile. METHODS: Open-label 14 patients chronic or ulcers. RESULTS: Groups 1 2 (55.5% 33.3%, respectively, comprising 60.1% total participants) received benefit using covering, there were no adverse reactions the tissue. CONCLUSION: helps decrease population Randomized, controlled studies may be warranted.